Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.57 |
| ▸ | MAPT | P10636 | 7/20 | 0.57 |
| ▸ | LMNA | P02545 | 4/20 | 0.57 |
| ▸ | HPGD | P15428 | 6/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.52 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17165585 | 1.00 | ALDH1A1 (0.57) | ALDH1A1MAPTLMNAHPGDMAPK1 | |
| SCHEMBL31498681 | 0.90 | ALDH1A1 (0.57) | ALDH1A1MAPTLMNAHPGDMAPK1 | |
| SCHEMBL23728786 | 0.88 | ALDH1A1 (0.55) | ALDH1A1MAPTLMNAHPGDMAPK1 | |
| SCHEMBL19136021 | 0.88 | ALDH1A1 (0.55) | ALDH1A1MAPTLMNAHPGDMAPK1 | |
| SCHEMBL15281425 | 0.88 | ALDH1A1 (0.55) | ALDH1A1MAPTLMNAHPGDMAPK1 | |
| SCHEMBL31498738 | 0.87 | ALDH1A1 (0.54) | ALDH1A1MAPTLMNAHPGDMAPK1 | |
| SCHEMBL30411459 | 0.86 | ALDH1A1 (0.53) | ALDH1A1MAPTLMNAHPGDMAPK1 | |
| SCHEMBL30012531 | 0.86 | ALDH1A1 (0.60) | ALDH1A1MAPTLMNAHPGDMAPK1 | |
| SCHEMBL18418518 | 0.84 | ALDH1A1 (0.51) | ALDH1A1MAPTLMNAHPGDMAPK1 | |
| SCHEMBL18418519 | 0.84 | ALDH1A1 (0.51) | ALDH1A1MAPTLMNAHPGDMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3129378-B1 | BROMODOMAIN-INHIBITING COMPOUNDS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME FOR PREVENTING OR TREATING A CANCER | KAINOS MEDICINE INC (KR) | 2019-06-26 | — | — | EP | disclosed |
| EP-3129378-B1 | BROMODOMAIN-INHIBITING COMPOUNDS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME FOR PREVENTING OR TREATING A CANCER | KAINOS MEDICINE INC (KR) | 2019-06-26 | — | — | EP | disclosed |
| US-9884874-B2 | Bromodomain-inhibiting compounds and pharmaceutical composition comprising same for preventing or treating a cancer | KAINOS MEDICINE, INC. (KR) | 2018-02-06 | — | — | US | disclosed |
| US-9884874-B2 | Bromodomain-inhibiting compounds and pharmaceutical composition comprising same for preventing or treating a cancer | KAINOS MEDICINE, INC. (KR) | 2018-02-06 | — | — | US | disclosed |
| US-9884874-B2 | Bromodomain-inhibiting compounds and pharmaceutical composition comprising same for preventing or treating a cancer | KAINOS MEDICINE, INC. (KR) | 2018-02-06 | — | — | US | disclosed |
| US-20170174702-A1 | BROMODOMAIN-INHIBITING COMPOUNDS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME FOR PREVENTING OR TREATING A CANCER | KAINOS MEDICINE, INC. (KR) | 2017-06-22 | — | — | US | disclosed |
| US-20170174702-A1 | BROMODOMAIN-INHIBITING COMPOUNDS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME FOR PREVENTING OR TREATING A CANCER | KAINOS MEDICINE, INC. (KR) | 2017-06-22 | — | — | US | disclosed |
| US-20170174702-A1 | BROMODOMAIN-INHIBITING COMPOUNDS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME FOR PREVENTING OR TREATING A CANCER | KAINOS MEDICINE, INC. (KR) | 2017-06-22 | — | — | US | disclosed |
| EP-3129378-A1 | BROMODOMAIN-INHIBITING COMPOUNDS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME FOR PREVENTING OR TREATING A CANCER | Kainos Medicine, Inc. (KR) | 2017-02-15 | — | — | EP | disclosed |
| WO-2015156601-A1 | BROMODOMAIN-INHIBITING COMPOUNDS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME FOR PREVENTING OR TREATING A CANCER | KAINOS MEDICINE, INC. (KR) | 2015-10-15 | — | — | WO | disclosed |
| WO-2015156601-A1 | BROMODOMAIN-INHIBITING COMPOUNDS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME FOR PREVENTING OR TREATING A CANCER | KAINOS MEDICINE, INC. (KR) | 2015-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174702-A1 | BROMODOMAIN-INHIBITING COMPOUNDS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME FOR PREVENTING OR TREATING A CANCER | BRDT, BRD4, BAZ2A | ALDH1A1 4118/4885MAPT 2395/4885LMNA 877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.